<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175224</url>
  </required_header>
  <id_info>
    <org_study_id>APL-101-01 (CBT-101-01)</org_study_id>
    <nct_id>NCT03175224</nct_id>
  </id_info>
  <brief_title>APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors</brief_title>
  <acronym>SPARTA</acronym>
  <official_title>Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apollomics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apollomics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary Phase 1 purpose of this study is to assess overall safety and tolerability and
      recommended Phase 2 dose (RP2D) of APL-101.

      The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals
      with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation
      Advanced Solid Tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, multi-center, global, open-label, 2-part study with a Dose Escalation
      Segment and Dose and Disease Expansion Cohorts study of APL-101, a c-MET inhibitor, to
      determine the recommended Phase 2 dose (RP2D) and dose limiting toxicities for APL-101, and
      to obtain preliminary efficacy and target engagement data, in subjects with NSCLC and
      advanced malignancies with c-Met dysregulation.

      c-MET dysregulation will be determined from historical results by molecular pre-screening
      evaluations to determine eligibility of enrollment for both the Dose Escalation Segment
      (Phase 1) and Dose and Disease Expansion Cohorts (Phase 2).

      Dose escalation will occur until a protocol defined dose limited toxicity (DLT) occurs and a
      tentative maximum tolerated dose (MTD) is determined.

      Once dose is determined, five cohort groups will be further evaluated:

        -  Cohort A-1: NSCLC EXON 14 skip mutation (c-Met na誰ve, 1L)

        -  Cohort A-2: NSCLC EXON 14 skip mutation (c-Met na誰ve, 2/3L),

        -  Cohort B: NSCLC EXON 14 skip mutation (c-Met experienced; progressed on prior c-Met
           inhibitor),

        -  Cohort C: basket of tumor types (with c-Met high-level amplifications),

        -  Cohort D: basket of tumor types (with c-Met fusions)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1: Subjects will be assigned to a dose level in the order of study entry. Treatment includes four planned dose levels (100 mg, 200 mg, 300 mg, and 400 mg).
Phase 2: Subjects will receive RP2D at 400mg daily dose (200mg BID).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the maximum tolerated dose (MTD) and the incidence of DLTs</measure>
    <time_frame>From the time of informed consent signature through Cycle 1 (28 days) completion</time_frame>
    <description>Adverse events, serious adverse events, and dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine response rate in Phase 2</measure>
    <time_frame>From time of informed consent signature through completion of Cycle 2 (1 cycle = 28 days)</time_frame>
    <description>Anti-tumor activity per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAE and AEs</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Adverse events, serious adverse events, and dose limiting toxicities according to the National Cancer Institute (NCI) Terminology Criteria for Adverse Events (CTCAE v4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Up to 2 months (1 cycle = 28 days)</time_frame>
    <description>AUC, 0 - infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>Up to 2 months (1 cycle = 28 days)</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax</measure>
    <time_frame>Up to 2 months (1 cycle = 28 days)</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Anti-tumor activity per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Anti-tumor activity per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Anti-tumor activity per RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Advanced Cancer</condition>
  <condition>Renal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>NSCLC</condition>
  <condition>Lung Cancer</condition>
  <condition>Brain Tumor</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APL-101 Oral Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-101 Oral Capsules</intervention_name>
    <description>Phase 1 Subjects will be assigned to a dose level of APL-101 in the order of study entry. Treatment includes 28-day cycles at four planned dose levels (100 mg, 200 mg, 300 mg and 400 mg). Each treatment cycle is administered by daily oral capsules taken every 12 hours.
Phase 2 Subjects will be given 400mg daily dose (200mg BID) of APL-101 capsules.</description>
    <arm_group_label>Single-Arm</arm_group_label>
    <other_name>PLB-1001</other_name>
    <other_name>CBI-3103</other_name>
    <other_name>Bozitinib</other_name>
    <other_name>CBT-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Able to understand and comply with study procedures, understand the risks involved,
             and provide written informed consent.

          -  For Phase 1, histologically and / or cytological confirmed unresectable or metastatic
             solid malignancy, refractory to standard therapies with no more than three prior lines
             of therapy.

          -  For Phase 2, five cohorts will be enrolled: Cohort A-1: NSCLC EXON 14 skip mutation
             (c-Met na誰ve) for first line treatment, Cohort A-2: NSCLC EXON 14 skip mutation (c-Met
             na誰ve) pretreated subjects with no more than 3 lines of prior therapy, Cohort B: NSCLC
             EXON 14 skip mutation (c-Met experienced; radiographic progression on prior c-Met
             inhibitor), Cohort C: basket of tumor types with c-Met high level amplification (NSCLC
             EXON 14 skip mutation excluded), Cohort D: basket of tumor type with c-Met fusions.

          -  Local/archival result (tissue and/or plasma) of a positive c-Met dysregulation is
             required

          -  Measurable disease according to RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  No chemotherapy treatments within at least 3 weeks prior to first dose of study
             treatment

          -  No planned major surgery within 4 weeks of first dose of APL-101

        Major Exclusion Criteria:

          -  Hypersensitivity to APL-101, excipients of the drug product, or other components of
             the study treatment regimen.

          -  Known mutation/gene rearrangement of EGFR (except for Cohort C), ALK, ROS1, RET, NTRK,
             KRAS, and BRAF.

          -  History of, or currently, or at risk for, cardiac disease (e.g., long QT syndrome [&gt;
             450 msec QTcF or concurrent treatment with any medication that prolongs QT interval).

          -  Unable to swallow orally administered medication whole.

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter drug absorption (e.g., Crohn's, ulcerative colitis, active
             inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption
             syndrome).

          -  Women who are breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Manlapaz-Espiritu</last_name>
    <role>Study Director</role>
    <affiliation>Senior Director, Clinical Operations</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Manlapaz-Espiritu</last_name>
    <phone>650-209-4055</phone>
    <email>Lenilyn.Espiritu@apollomicsinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gavin Choy, PharmD, MBA</last_name>
    <phone>650-209-4055</phone>
    <email>gavin.choy@apollomicsinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Mozlen</last_name>
      <phone>480-256-5481</phone>
      <email>eileen.molzen@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jiaxin Niu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela McClure Study Coordinator</last_name>
      <phone>480-342-6076</phone>
      <email>Mcclure.pamela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mahesh K Seetharam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez Study Coordinator</last_name>
      <phone>323-865-0212</phone>
      <email>xiomara.menendez@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise DeMaio Study Coordinator</last_name>
      <email>Denise.A.DeMaio@ChristianaCare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guarino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Georgiou Study Coordinator</last_name>
      <phone>904-953-8667</phone>
      <email>georgiou.Andrea@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kabir Mody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Iorio, MS</last_name>
      <phone>407-303-7325</phone>
      <email>mailto:Rebecca.Iorio@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Mark Socinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Wright</last_name>
      <email>pwright@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Viralkumar Bhanderi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bar-nur</last_name>
      <email>jbar-nur@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Eric Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Birgin Study Coordinator</last_name>
      <phone>507-266-7093</phone>
      <email>Birgin.ann@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Sani H Kizilbash, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Minnesota Community Oncology Research Consortium</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grant Gunderson Program Manager</last_name>
      <phone>952-993-1555</phone>
      <email>grant.gunderson@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Lerner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Fogal</last_name>
      <phone>314-362-1518</phone>
      <email>clfogal@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Siddhartha Devarakonda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Mayer</last_name>
      <phone>919-966-4091</phone>
      <email>allie.mayer@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Claire Dees, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kettering Health Network</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Keeton Study Coordinator</last_name>
      <email>kelly.keeton@ketteringhealth.org</email>
    </contact>
    <investigator>
      <last_name>Emily Franks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Adams Clinical Research Coordinator</last_name>
      <phone>864-603-6219</phone>
      <email>amy_adams@bshi.org</email>
    </contact>
    <investigator>
      <last_name>Robert Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon and HCA Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Callaway</last_name>
      <phone>615-524-7283</phone>
      <email>brittany.callaway@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>David Spigel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Macon Clinical Research Coordinator</last_name>
      <phone>253-403-0791</phone>
      <email>smmacon@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Slim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Cancer Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia McEwuen Study Coordinator, BSN</last_name>
      <phone>304-293-1683</phone>
      <email>smcewuen@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed Almubarak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Warnell Study Coordinator</last_name>
      <phone>608-265-0811</phone>
      <email>brittany.warnell@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Burkard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.apollomicsinc.com</url>
    <description>Company website for Apollomics, Inc.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Relapsed Solid Tumor</keyword>
  <keyword>Recurrent Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

